SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CRIS, Curis (formerly CBMI)
CRIS 1.150+2.7%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bubba who wrote (77)9/22/1997 1:35:00 AM
From: Larry Liebman   of 668
 
Having managed to lose my notes from speaking with company rep. on Thursday, here is the best recollection:

(1) Stryker is expected to file a P.M.A. in Novemeber/December regarding the OP-1 bone graft substitute product. Styker intends to report comprehensive data at American Orthopedic Assn. convention in 3/98.

(2) Results from preclinical studies for OP-1 regarding neurological benefit are extremely encouraging. The rep. reported that Op-1 appeared to encourage the growth of dendrites. Additional data will be released ar a neurological conference in November. CBMI strongly believes that they will be able to partner this application.

(3) OP-1 for kidney failure, partnered with Biogen, will not hit the clinic until the first half of '98. Expectations had been for late '97. Rep. reported that decision had been made to target the "acute" market, which is reportedly a far more significant one, resulting in a delay. More info. will be released at a conference later this year.

(4) Company has significantly increased their R&D. Prior 3 months were almost as great as the 6 months for last year.

I apologize for not having the precise data. I encourage interested parties to call the company and get the info.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext